ReviewFrontiers in pharmacology2023
Traditional Chinese medicine for treatment of sepsis and related multi-organ injury.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Therapeutic efficacy and mechanisms of Xuebijing inFrontiers in pharmacology · 2025Pooled it
- The impact of traditional Chinese medicine on gastrointestinal dysfunction in sepsis patients: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Moxibustion combined with anti-PD-1 antibodies improves immunosuppression in septic mice potentially through the PD-1/PD-L1 pathway.Immunologic research · 2026Article
- Dachaihu decoction alleviates septic liver injury by modulating the intestinal barrier dysfunction and suppressing the NF-κB/NLRP3/Caspase-1 signaling pathway.Chinese medicine · 2026Article
- Modulation of mitochondrial quality control in sepsis by traditional Chinese medicine: mechanistic insights and translational perspectives.Frontiers in pharmacology · 2026Review
- Targeting ferroptosis in sepsis-induced cardiomyopathy: mechanisms and therapeutic potential of traditional Chinese Medicine.Frontiers in pharmacology · 2026Review
- Sepsis and the Liver.Diseases (Basel, Switzerland) · 2025Review
- Intervention effect of curcumin on sepsis-associated acute kidney injury via regulation of p300 expression and protein lactylation.BMC immunology · 2025Article
- Traditional Chinese medicine for sepsis: advancing from evidence to innovative drug discovery.Critical care (London, England) · 2025Review
- Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Delivery of miR-26a-5p by Subcutaneous Adipose Tissue-Derived Extracellular Vesicles Alleviates Acute Lung Injury in Mice Through CHUK/NF-κB Pathway.International journal of nanomedicine · 2025Article
- Xijiao Dihuang Decoction for Sepsis-Induced Acute Lung Injury: Network Pharmacology and Molecular Dynamics Insights.Journal of inflammation research · 2025Article
- Investigating the Therapeutic Mechanisms of Honeysuckle (China) in Sepsis Through Network Pharmacology and Experimental Validation.Infection and drug resistance · 2025Article
- Therapeutic Targets and Immune Mechanisms of Yinghuang Decoction in Sepsis: Integrating Network Pharmacology, Molecular Docking, and Pharmacokinetic Approaches.International journal of general medicine · 2025Article
- Article
- Multi-Dimensional Characterization of Programmed Cell Death Patterns for Prognostic Stratification and Therapeutic Insights in Sepsis.ImmunoTargets and therapy · 2025Article
- Exploring the potential mechanism of Radix Bupleuri in the treatment of sepsis: a study based on network pharmacology and molecular docking.BMC complementary medicine and therapies · 2024Article
- Exploring the potential mechanisms of Rehmannia glutinosa in treating sepsis based on network pharmacology.BMC infectious diseases · 2024Article
- Myricanol attenuates sepsis-induced inflammatory responses by nuclear factor erythroid 2-related factor 2 signaling and nuclear factor kappa B/mitogen-activated protein kinase pathway via upregulating Sirtuin 1.Inflammopharmacology · 2024Article
- Danlou tablet alleviates sepsis-induced acute lung and kidney injury by inhibiting the PARP1/HMGB1 pathway.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a common but critical illness in patients admitted to the intensive care unit and is associated with high mortality. Although there are many treatments for sepsis, specific and effective therapies are still lacking. For over 2,000 years, traditional Chinese medicine (TCM) has played a vital role in the treatment of infectious diseases in Eastern countries. Both anecdotal and scientific evidence show that diverse TCM preparations alleviate organ dysfunction caused by sepsis by inhibiting the inflammatory response, reducing oxidative stress, boosting immunity, and maintaining cellular homeostasis. This review reports on the efficacy and mechanism of action of various TCM compounds, herbal monomer extracts, and acupuncture, on the treatment of sepsis and related multi-organ injury. We hope that this information would be helpful to better understand the theoretical basis and empirical support for TCM in the treatment of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.